UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (100) 100
life sciences & biomedicine (96) 96
oncology (65) 65
humans (63) 63
female (50) 50
male (47) 47
aged (42) 42
middle aged (41) 41
lung neoplasms - drug therapy (32) 32
carcinoma, non-small-cell lung - drug therapy (30) 30
adult (28) 28
lung cancer (28) 28
antineoplastic agents - therapeutic use (24) 24
lung neoplasms - pathology (23) 23
aged, 80 and over (22) 22
immunotherapy (19) 19
treatment outcome (19) 19
lung neoplasms - genetics (18) 18
chemotherapy (17) 17
antibodies, monoclonal - therapeutic use (15) 15
care and treatment (15) 15
lung cancer, non-small cell (15) 15
patients (15) 15
research (15) 15
carcinoma, non-small-cell lung - genetics (14) 14
mutation (14) 14
respiratory system (14) 14
cancer (13) 13
tumors (13) 13
cancer therapies (12) 12
carcinoma, non-small-cell lung - pathology (12) 12
metastasis (12) 12
non-small cell lung carcinoma (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
neoplasm staging (11) 11
parasitology (11) 11
antibodies, monoclonal - adverse effects (10) 10
antineoplastic agents - adverse effects (10) 10
apoptosis (10) 10
usage (10) 10
cohort studies (9) 9
lung neoplasms - metabolism (9) 9
nsclc (9) 9
studies (9) 9
abridged index medicus (8) 8
analysis (8) 8
lung neoplasms - mortality (8) 8
prognosis (8) 8
receptor, epidermal growth factor - genetics (8) 8
brain neoplasms - secondary (7) 7
carcinoma, non-small-cell lung - metabolism (7) 7
clinical trials (7) 7
drug therapy (7) 7
general & internal medicine (7) 7
health aspects (7) 7
immunology (7) 7
melanoma (7) 7
non-small cell lung cancer (7) 7
pd-l1 (7) 7
pd-l1 protein (7) 7
adenocarcinoma - drug therapy (6) 6
animals (6) 6
antineoplastic agents - pharmacology (6) 6
carcinoma, non-small-cell lung - mortality (6) 6
carcinoma, non-small-cell lung - secondary (6) 6
cell line, tumor (6) 6
disease-free survival (6) 6
dosage and administration (6) 6
follow-up studies (6) 6
kaplan-meier estimate (6) 6
neoplasms - drug therapy (6) 6
original reports (6) 6
pd-1 protein (6) 6
programmed cell death 1 receptor - antagonists & inhibitors (6) 6
protein kinase inhibitors - therapeutic use (6) 6
respiratory tract diseases (6) 6
retrospective studies (6) 6
survival (6) 6
survival analysis (6) 6
adenocarcinoma - pathology (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
b7-h1 antigen - antagonists & inhibitors (5) 5
b7-h1 antigen - biosynthesis (5) 5
b7-h1 antigen - metabolism (5) 5
biomarkers (5) 5
ectoparasitology (5) 5
erlotinib (5) 5
hematology, oncology and palliative medicine (5) 5
immune checkpoint (5) 5
lung neoplasms - immunology (5) 5
medicine, general & internal (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
parasite hosts (5) 5
pathology (5) 5
receptor protein-tyrosine kinases - genetics (5) 5
solid tumors (5) 5
survival rate (5) 5
time factors (5) 5
young adult (5) 5
zoology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2015, Volume 373, Issue 17, pp. 1627 - 1639
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2018, Volume 379, Issue 21, pp. 2027 - 2039
In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Organophosphorus Compounds - adverse effects | Crizotinib - therapeutic use | Lung Neoplasms - chemistry | Anaplastic Lymphoma Kinase - analysis | Kaplan-Meier Estimate | Organophosphorus Compounds - therapeutic use | Crizotinib - adverse effects | Pyrimidines - therapeutic use | Progression-Free Survival | Pyrimidines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Crizotinib | Cancer patients | Safety and security measures | Development and progression | Dosage and administration | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Nuclear magnetic resonance--NMR | Medical imaging | Statistical analysis | Lung cancer | Non-small cell lung carcinoma | Metastasis | Radiation therapy | Lymphoma | Cancer therapies | Chemotherapy | Technical communication | Mutation | Protein-tyrosine kinase | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article